An anti-CD14 antibody (Atibuclimab, Implicit Bioscience Ltd) has been studied as a targeted anti-inflammatory strategy in patients with amyotrophic lateral sclerosis (NCT04309604),29 arrhythmogenic cardiomyopathy (NCT06275893),30 and COVID-19 pneumonia (NCT04391309),31 showing a favorable safety profile, with clinical trials ongoing in arrhythmogenic cardiomyopathy and acute decompensated heart failure. Here, CD14 is linked to amyotrophic lateral sclerosis.